Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | IMVT |
---|---|---|
09:32 ET | 8344 | 27 |
09:34 ET | 2814 | 27.14 |
09:36 ET | 2789 | 27.22 |
09:38 ET | 600 | 27.13 |
09:39 ET | 2503 | 27.08 |
09:41 ET | 830 | 27.32 |
09:43 ET | 200 | 27.26 |
09:45 ET | 2300 | 27.28 |
09:48 ET | 600 | 27.23 |
09:52 ET | 600 | 27.09 |
09:54 ET | 2764 | 27.285 |
09:56 ET | 857 | 27.245 |
09:57 ET | 1026 | 27.19 |
09:59 ET | 15463 | 27.24 |
10:01 ET | 100 | 27.275 |
10:03 ET | 200 | 27.23 |
10:06 ET | 1314 | 27.48 |
10:08 ET | 409 | 27.44 |
10:10 ET | 4983 | 27.425 |
10:12 ET | 300 | 27.47 |
10:15 ET | 1765 | 27.48 |
10:17 ET | 3696 | 27.3 |
10:19 ET | 100 | 27.315 |
10:21 ET | 1620 | 27.35 |
10:24 ET | 200 | 27.38 |
10:26 ET | 100 | 27.35 |
10:28 ET | 100 | 27.32 |
10:30 ET | 800 | 27.33 |
10:32 ET | 500 | 27.35 |
10:33 ET | 629 | 27.34 |
10:35 ET | 100 | 27.36 |
10:37 ET | 400 | 27.33 |
10:39 ET | 1018 | 27.29 |
10:42 ET | 400 | 27.3 |
10:44 ET | 1317 | 27.355 |
10:46 ET | 600 | 27.38 |
10:48 ET | 800 | 27.35 |
10:51 ET | 1263 | 27.36 |
10:53 ET | 1400 | 27.31 |
10:57 ET | 300 | 27.33 |
11:00 ET | 400 | 27.315 |
11:04 ET | 1400 | 27.43 |
11:06 ET | 4538 | 27.35 |
11:08 ET | 1180 | 27.35 |
11:09 ET | 694 | 27.4788 |
11:11 ET | 531 | 27.49 |
11:13 ET | 3456 | 27.4125 |
11:15 ET | 400 | 27.39 |
11:18 ET | 100 | 27.39 |
11:20 ET | 6825 | 27.24 |
11:22 ET | 204 | 27.29 |
11:24 ET | 789 | 27.23 |
11:26 ET | 1173 | 27.27 |
11:27 ET | 100 | 27.255 |
11:29 ET | 2883 | 27.25 |
11:31 ET | 400 | 27.255 |
11:33 ET | 3300 | 27.26 |
11:36 ET | 1190 | 27.29 |
11:38 ET | 347 | 27.275 |
11:42 ET | 100 | 27.28 |
11:44 ET | 3907 | 27.19 |
11:45 ET | 605 | 27.25 |
11:47 ET | 100 | 27.27 |
11:49 ET | 300 | 27.27 |
11:51 ET | 643 | 27.21 |
11:54 ET | 400 | 27.25 |
11:56 ET | 626 | 27.28 |
11:58 ET | 1050 | 27.34 |
12:00 ET | 1900 | 27.32 |
12:02 ET | 300 | 27.305 |
12:03 ET | 200 | 27.34 |
12:05 ET | 600 | 27.29 |
12:07 ET | 100 | 27.33 |
12:09 ET | 2001 | 27.35 |
12:12 ET | 500 | 27.37 |
12:14 ET | 500 | 27.4 |
12:16 ET | 1289 | 27.35 |
12:18 ET | 100 | 27.37 |
12:20 ET | 2200 | 27.35 |
12:21 ET | 3719 | 27.355 |
12:23 ET | 700 | 27.35 |
12:25 ET | 1200 | 27.335 |
12:27 ET | 900 | 27.37 |
12:30 ET | 625 | 27.48 |
12:32 ET | 1003 | 27.47 |
12:34 ET | 1779 | 27.4 |
12:36 ET | 8724 | 27.4 |
12:38 ET | 2919 | 27.385 |
12:39 ET | 600 | 27.35 |
12:41 ET | 1009 | 27.32 |
12:43 ET | 400 | 27.34 |
12:45 ET | 1200 | 27.39 |
12:48 ET | 503 | 27.39 |
12:50 ET | 1854 | 27.51 |
12:52 ET | 1800 | 27.52 |
12:54 ET | 100 | 27.53 |
12:56 ET | 250 | 27.492 |
12:57 ET | 3879 | 27.4 |
12:59 ET | 926 | 27.39 |
01:01 ET | 100 | 27.35 |
01:03 ET | 1700 | 27.36 |
01:06 ET | 2850 | 27.36 |
01:08 ET | 200 | 27.34 |
01:12 ET | 1750 | 27.35 |
01:14 ET | 300 | 27.35 |
01:15 ET | 100 | 27.345 |
01:17 ET | 200 | 27.37 |
01:19 ET | 100 | 27.32 |
01:21 ET | 5358 | 27.34 |
01:24 ET | 100 | 27.36 |
01:26 ET | 500 | 27.375 |
01:28 ET | 4139 | 27.375 |
01:30 ET | 1919 | 27.38 |
01:32 ET | 3430 | 27.35 |
01:33 ET | 200 | 27.34 |
01:35 ET | 3110 | 27.37 |
01:39 ET | 2500 | 27.35 |
01:42 ET | 2220 | 27.3 |
01:44 ET | 900 | 27.31 |
01:46 ET | 300 | 27.3 |
01:48 ET | 200 | 27.3 |
01:50 ET | 300 | 27.3 |
01:51 ET | 930 | 27.32 |
01:53 ET | 2281 | 27.34 |
01:55 ET | 400 | 27.36 |
01:57 ET | 1799 | 27.34 |
02:00 ET | 1474 | 27.32 |
02:02 ET | 100 | 27.325 |
02:04 ET | 200 | 27.33 |
02:06 ET | 4702 | 27.31 |
02:08 ET | 715 | 27.3 |
02:09 ET | 1146 | 27.3 |
02:11 ET | 758 | 27.33 |
02:15 ET | 300 | 27.36 |
02:18 ET | 603 | 27.39 |
02:20 ET | 2000 | 27.34 |
02:22 ET | 5280 | 27.3 |
02:24 ET | 1630 | 27.3 |
02:26 ET | 3800 | 27.14 |
02:27 ET | 3400 | 27.18 |
02:29 ET | 3902 | 27.275 |
02:31 ET | 677 | 27.29 |
02:33 ET | 200 | 27.3 |
02:38 ET | 1177 | 27.255 |
02:40 ET | 2746 | 27.29 |
02:42 ET | 3816 | 27.27 |
02:44 ET | 1220 | 27.26 |
02:45 ET | 100 | 27.255 |
02:47 ET | 3127 | 27.26 |
02:49 ET | 1321 | 27.24 |
02:51 ET | 4815 | 27.16 |
02:54 ET | 1292 | 27.21 |
02:56 ET | 2432 | 27.21 |
02:58 ET | 955 | 27.23 |
03:00 ET | 2267 | 27.185 |
03:02 ET | 3138 | 27.2 |
03:03 ET | 3005 | 27.14 |
03:05 ET | 1802 | 27.13 |
03:07 ET | 1651 | 27.16 |
03:09 ET | 6424 | 27.22 |
03:12 ET | 969 | 27.14 |
03:14 ET | 1309 | 27.08 |
03:16 ET | 1401 | 27.08 |
03:18 ET | 240 | 27.095 |
03:20 ET | 7743 | 27.17 |
03:21 ET | 7202 | 27.21 |
03:23 ET | 2453 | 27.21 |
03:25 ET | 3071 | 27.24 |
03:27 ET | 1043 | 27.21 |
03:30 ET | 1800 | 27.21 |
03:32 ET | 2501 | 27.22 |
03:34 ET | 5250 | 27.24 |
03:36 ET | 940 | 27.23 |
03:38 ET | 348 | 27.22 |
03:39 ET | 3550 | 27.25 |
03:41 ET | 4268 | 27.24 |
03:43 ET | 1500 | 27.24 |
03:45 ET | 4785 | 27.23 |
03:48 ET | 5621 | 27.24 |
03:50 ET | 4468 | 27.24 |
03:52 ET | 7773 | 27.205 |
03:54 ET | 8841 | 27.205 |
03:56 ET | 7826 | 27.23 |
03:57 ET | 10431 | 27.28 |
03:59 ET | 28634 | 27.29 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Immunovant Inc | 4.0B | -14.5x | --- |
Avidity Biosciences Inc | 4.1B | -13.2x | --- |
BridgeBio Pharma Inc | 4.4B | -7.2x | --- |
Merus NV | 3.8B | -20.8x | --- |
Crinetics Pharmaceuticals Inc | 3.5B | -11.9x | --- |
Dyne Therapeutics Inc | 3.4B | -8.6x | --- |
Immunovant, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. It is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD). Its lead product candidate IMVT-1402 has also been observed to reduce IgG antibody levels in a Phase I clinical trial conducted in healthy adults. IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.0B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 146.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.72 |
EPS | $-1.89 |
Book Value | $4.24 |
P/E Ratio | -14.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.